James L. Zehnder, M.D.
Academic Appointments
- Professor - Med Center Line, Pathology
- Member, Stanford Cancer Institute
- Professor - Med Center Line, Medicine - Hematology
Key Documents
Contact Information
-
Clinical Offices
Hematology Clinic Cancer Center 875 Blake Wilbur Dr Clinic C H1507 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 498-5030Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 723-9232Alternate Contact Angie Banez Administrative Assistant Email Tel Work 6-8002Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Hematology
- Pathology
- Pathology and Laboratory Medicine
Administrative Appointments
- Attending Physician, Hematology Service, Stanford Hospital (1995 - present)
- Director, Coagulation and Molecular Pathology Laboratories, Stanford Hospital (1995 - present)
Professional Education
| Fellowship: | Stanford University CA (1993) |
| Residency: | Stanford University CA (1988) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1987) |
| Internship: | Stanford University School of Medicine CA (1985) |
| Medical Education: | Tufts University MA (1984) |
| MD: | Tufts Univ. School of Medicine, Medicine (1984) |
Scientific Focus
Current Research Interests
Active projects:
1. Translating advances in genomics for patient care. Currently we are using next generation sequencing approaches to characterize the clonal population in T or B cell cancers,
how theses cells reconstitute following transplantation, and their role in disease progression and complications such as graft-versus-host disease.
2.Using traditional and next generation genomic approaches to characterize the molecular basis of myeloproliferative neoplasms
3. Molecular basis of pediatric immune thrombocytopenia - underlying etiology, what differentiates the 80% who spontaneously remit form those who develop chronic disease, identification of molecular biomarkers predicting response to thrombopoietin agonists
4. Whole genome studies of families with interesting pedigrees - inherited thrombocytopenia, thrombosis following exposure to oral contraceptives
Clinical Trials
- Recruiting Bone Marrow Grafting for Leukemia and Lymphoma
- Recruiting Integrated Whole-Genome Analysis of Hematologic Disorders
- Not Recruiting Phase II Temozolomide in Acute Myeloid Leukemia Patient Age >= 60 Yrs & Poor Risk/Refractory Disease
- Not Recruiting Evaluation of Pathwork Tissue of Origin (TOO) Test for Human Malignancies
- Recruiting A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Publications
- 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma. 2013; (2): 408-10
- A distinct evolution of the T cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood. 2013
- Desktop transcriptome sequencing from archival tissue to identify clinically relevant translocations. Am J Surg Pathol. 2013; (6): 796-803
- Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother. 2013; (2): 151-8
- Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma. Adv Anat Pathol. 2013; (3): 137-40
- Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013
Help
Trial Administration